Section Arrow
ATYR.NASDAQ
- aTyr Pharma Inc
Quotes are at least 15-min delayed:2024/06/18 08:26 EDT
Last
 1.77
-0.06 (-3.28%)
Day High 
1.87 
Prev. Close
1.83 
1-M High
2.09 
Volume 
336.23K 
Bid
1.72
Ask
1.77
Day Low
1.72 
Open
1.83 
1-M Low
1.65 
Market Cap 
126.29M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.89 
20-SMA 1.87 
50-SMA 1.76 
52-W High 2.44 
52-W Low 1.0801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.88/-0.79
Enterprise Value
140.06M
Balance Sheet
Book Value Per Share
1.22
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
353.00K
Operating Revenue Per Share
0.15
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.4288-0.0209-4.65%-- 
MBIOMustang Bio0.75+0.62+476.92%-- 
NLSPNLS Pharmaceutics Ltd0.1483+0.034378+30.18%-- 
SCNIScinai Immunotherapeutics Ltd.5.6+2.11+60.46%-- 
AZTRAzitra0.2337+0.0844+56.53%-- 
Quotes are at least 15-min delayed:2024/06/18 08:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.